| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5614038 | Journal of Cardiac Failure | 2017 | 12 Pages |
Abstract
The availability of effective pangenotypic therapy for HCV may expand donor availability. The feasibility of early versus late treatment of HCV remains to be determined through formalized protocols. We hypothesize pharmacoeconomics to be the greatest limitation to widespread availability of this promising tool.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Robert L. MD, PhD, Teena PharmD, Suzanne Y. MD, James F. MD, Sumeet K. MD, Brian MD, Susan M. MD, Gonzalo V. MD, Shelley A. MD,